Table S1.
Clinical details of the recruited PSD and stroke subjects
| Variables | PSD | Stroke | Statistics | df | P-valuea | |
|---|---|---|---|---|---|---|
| Training set | Depression subtype (major/minor) | 14/18 | _ | _ | _ | _ |
| Antidepressants treatment (Y/N) | 10/22 | _ | _ | _ | _ | |
| Stroke subtype (ischemia/hemorrhage) | 21/11 | 25/10 | _ | _ | _ | |
| Time poststroke (days)c | 53 (30, 150) | 33 (21, 33) | Z=−2.3 | 1 | 0.023 | |
| Modified Rankin Scaleb | 2.8±1.4 | 2.6±1.4 | t=0.5 | 65 | 0.594 | |
| NASID treatment (Y/N) | 15/17 | 20/15 | χ2=0.7 | 1 | 0.401 | |
| Sleep meds treatment (Y/N) | 2/30 | N | χ2=2.3 | 1 | 0.133 | |
| Hypertention (Y/N) | 30/2 | 30/5 | χ2=1.2 | 1 | 0.283 | |
| Hyperlipidaemia (Y/N) | 8/24 | 8/27 | χ2=0.04 | 1 | 0.837 | |
| Diabetes (Y/N) | 10/22 | 12/23 | χ2=0.07 | 1 | 0.792 | |
| Test set | Depression subtype (major/minor) | 4/6 | _ | _ | _ | _ |
| Antidepressants treatment (Y/N) | 4/6 | _ | _ | _ | _ | |
| Stroke subtype (ischemia/hemorrhage) | 5/5 | 0/11 | _ | _ | _ | |
| Time poststroke (days)b | 35.5±16.4 | 33.3±15.2 | t=0.3 | 19 | 0.750 | |
| Modified Rankin Scaleb | 2.2±0.9 | 2.5±1.5 | t=−0.5 | 19 | 0.650 | |
| NASID treatment (Y/N) | 4/6 | 10/1 | χ2=6.1 | 1 | 0.013 | |
| Sleep meds treatment (Y/N) | 2/8 | N | χ2=10.8 | 1 | 0.001 | |
| Hypertention (Y/N) | 7/3 | 9/2 | χ2=0.4 | 1 | 0.525 | |
| Hyperlipidaemia (Y/N) | 3/7 | 3/8 | χ2=0.02 | 1 | 0.890 | |
| Diabetes (Y/N) | 4/6 | 5/6 | χ2=0.1 | 1 | 0.801 |
Notes: aTwo-tailed student test for continuous variables (Modified Rankin Scale); Chi-square analyses for categorical variables (NASID treatment, sleep meds treatment, hypertension, hyperlipidaemia, diabetes). Time poststroke was analyzed by Mann–Whitney test in training set, and analyzed by two-tailed student test in test set. bValues expressed as the mean ± SD (range). cValues expressed as median (25%, 75%) quartiles.
Abbreviations: PSD, post-stroke depression; Y/N, Yes/No.